Expanded Access of Dupilumab in Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy Previously Treated With Linvoseltamab

Key Inclusion Criteria 1. Eligible participants for this program consist of adults who have completed the End of Study (EOS) visit in the parent phase 1 study, R5458-668-ALG-2219 (NCT06369467) 2. Administration of first dose of EAP dupilumab occurs as defined in the protocol Key Exclusion Criteria 1. Participants who, during the parent study (R5458-668-ALG-2219 \[NCT06369467\]), developed a Serious Adverse Event (SAE) and/or Adverse Event (AE) as defined in the protocol 2. Any temporary discontinuation of study drug dupilumab lasting \>2 weeks during the parent study R5458-668-ALG-2219 (NCT06369467) 3. Greater than 2 weeks since last administration of study drug dupilumab from the parent study R5458-668-ALG-2219 (NCT06369467) NOTE: Other protocol defined inclusion/exclusion criteria apply.